|
May 21, 2002
Cellomics Inc. Takes High Content Screening to a
New Dimension with its vHCSTM Information Management
Software Suite
Pittsburgh, PA - Cellomics, Inc. announced today
the launch of the new dimension in High Content Screening
(HCS) that accelerates "idea to discovery."
Virtual High Content Screening (vHCS) permits customers
to distribute and expand HCS capability throughout the
enterprise using any desktop PC to perform vHCS on data
generated from any HCS instrument anywhere in the organization.
Recognizing the need for expanded access to state-of-the-art
cell analysis technology, along with the ever-increasing
need for connectivity, Cellomics’ vHCS Information
Management Software Suite enables global HCS capabilities
that are aligned with research and screening workflow
patterns. As the pioneer in HCS, Cellomics has extended
its industry standard platform with a suite of new software
tools to satisfy workflow needs in cellular-based discovery.
"Our vHCS Information Management Software Suite
will become the backbone of all High Content Screening
programs," stated Dr. Albert Gough, VP of Research
and Development. "Our customers will be able to
access, visualize, analyze and even perform new virtual
assays on existing data from anywhere in the organization
from a desktop PC."
"Our vHCS suite of software tools includes vHCS-View
that allows visualization of HCS assay results; vHCS-Build
that creates, manages and analyzes assay data; vHCS-Scan
that permits re-scanning of existing cellular image
data with any biological application; and vHCS-CellSpace
that rapidly discovers cellular relationships identified
in the scientific literature," stated Mark Collins,
Senior Commercial Manager, HCS Software and Informatics.
Cellomics, Inc. is pioneering the field of cellular
knowledge extraction. Its unique technology, referred
to as High Content Screening, integrates fluorescent
reagents, kits, cell lines, multi-parametric assays,
HCS instrumentation (both fixed end-point and kinetics
systems), and informatics tools used to achieve a flexible,
broadly applicable platform for users in the life sciences.
This automated platform, when applied to lead optimization,
predictive toxicology, and new target validation, is
proving to reduce the "idea-to-discovery"
cycle time in drug discovery, while increasing the probability
of the therapeutic success of leads. Currently, Cellomics’
proprietary ArrayScan® HCS Systems are in use at
multiple sites within the top ten pharmaceutical companies
in the world, as well as several additional leading
pharmaceutical and biotechnology companies, and academic
centers.
For collaborative programs on Cellomics’ new dimension
of HCS and other information, contact:
Terence Brady
Corporate Communications
Cellomics, Inc.
100 Technology Drive
Pittsburgh, PA 15219
412-770-2200 x2237
412-770-2240 (fax)
tbrady@cellomics.com
www.cellomics.com
|
